Drug Search Results
More Filters [+]


Alternative Names: rifampicin, rifampin, rifadin, rimactane, rifampicine, rimactazid, rifinah, rifampicina, rifamate, rifater
Latest Update: 2024-06-10
Latest Update Note: News Article

Product Description

Rifabutin is a derivative of rifamycin S with activity against mycobacteria including atypical organisms such as Mycobacterium avium and M. intracellulare, also referred to as Mycobacterium avium-intracellulare complex (MAC). To date, rifabutin is the only drug to have been studied in large prospective placebo-controlled trials that has been shown to significantly reduce the incidence of disseminated MAC infection when administered prophylactically as a single agent to patients with acquired immune deficiency syndrome (AIDS). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7521834/)

Mechanisms of Action: CYP3A4 Activator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rifampicin

Countries in Clinic: Australia, Canada, China, Comoros, France, Japan, Korea, Madagascar, South Africa, Spain, United Kingdom, United States

Active Clinical Trial Count: 57

Highest Development Phases

Phase 3: Fractures, Open|Hidradenitis Suppurativa|Leprosy|Tuberculosis, Pulmonary

Phase 2: Coinfection|HIV Infections

Phase 1: Acute Myeloid Leukemia|Acute Pain|Alzheimer Disease|Arthritis, Rheumatoid|Bladder Cancer|Breast Cancer|COVID-19|Chronic Pain|Erectile Dysfunction|Esophageal Cancer|Evans Syndrome|Fatty Liver, Alcoholic|Geographic Atrophy|Healthy Volunteers|Insomnia|Low Back Pain|Lymphoma|Lymphoma, B-Cell|Neuralgia|Non-Small-Cell Lung Cancer|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Oncology Unspecified|Pain Unspecified|Pain, Postoperative|Parkinson's Disease|Pneumonia|Prostate Cancer|Small Cell Lung Cancer|Type 2 Diabetes|Urinary Calculi



Trial Status


Primary Completion Date

Probability of Success



Not yet recruiting

Fractures, Open




Not yet recruiting

Hidradenitis Suppurativa





Tuberculosis, Pulmonary|HIV Infections|Coinfection




Not yet recruiting

Tuberculosis, Pulmonary


Recent News Events